Personalized cancer medicine uses molecular biomarkers for standard-of-care treatment stratification, such as activating BRAF mutations for the treatment of melanoma with BRAF inhibitors.1 In parallel, it has become evident that therapeutic strategies with targeted drugs are no longer specific for the treatment of distinct entities but rather for particular molecular profiles across different cancers.2-4 Thus, testing for single-drug targets can provide therapeutic information, but its predictive value may vary between entities. Here, BRAF is linked to melanoma.